WO1996000394A1 - Procede de preparation de particules magnetiques utilisees pour realiser des analyses biologiques - Google Patents

Procede de preparation de particules magnetiques utilisees pour realiser des analyses biologiques Download PDF

Info

Publication number
WO1996000394A1
WO1996000394A1 PCT/IB1995/000502 IB9500502W WO9600394A1 WO 1996000394 A1 WO1996000394 A1 WO 1996000394A1 IB 9500502 W IB9500502 W IB 9500502W WO 9600394 A1 WO9600394 A1 WO 9600394A1
Authority
WO
WIPO (PCT)
Prior art keywords
glutaraldehyde
antibody
particles
excess
paramagnetic particle
Prior art date
Application number
PCT/IB1995/000502
Other languages
English (en)
Other versions
WO1996000394B1 (fr
Inventor
Steve C. S. Chang
Original Assignee
Ciba Corning Diagnostics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Corning Diagnostics Corp. filed Critical Ciba Corning Diagnostics Corp.
Priority to AU25736/95A priority Critical patent/AU2573695A/en
Publication of WO1996000394A1 publication Critical patent/WO1996000394A1/fr
Publication of WO1996000394B1 publication Critical patent/WO1996000394B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Definitions

  • Magnetic particles have been used as a tool for separation in biological systems for over twenty years (Robinson PJ et al. in Biotech. Bioengng 15:603-606,1973). Their use in immunoassays has been known for over ten years.
  • the early work by Whitehead et al (U.S. Patents 4,554,088, 4,695,393 and others) described a technique for preparation of the particles which utilized silane amine as the coating material and immobilized biological materials such as antibody on the coated particles.
  • the current technique used for immobilization as recommended by the current supplier of silanized particles involves activating the magnetic particles with glutaraldehyde, using 2 milligrams of glutaraldehyde per milligram of particles, allowing the reaction to proceed for 3 hours. Following this, the glutaraldehyde activated particles are mixed with antibody for 16 to 24 hours. (See Advanced Magnetics Product Manual, 1993-1994.) Summary of the Invention
  • the new process involves the use of much lower concentration of glutaraldehyde (approximately ten times less) , and surprisingly requires much less time, than was used previously to activate the particles.
  • the benefits of the novel process are: (1) It is a more efficient method of removing the excessive glutaraldehyde from the reaction system, and it eliminates the quenching step after antibody immobilization. (2) The activation process can be completed in a much shorter time than in the past, even though there is a significant reduction in glutaraldehdye concentration, which allows for the antibody immobilization step to be completed within one working day instead of two. (3) The resulting particles give 15 to 74% improvement of the sensitivity, which is observed in some immunochemical assays.
  • Figure 1 shows Glutaraldehyde Optimization, in terms of RLU bound to reflect the binding capacity of the finished particles as a function of glutaraldehyde concentration, which is expressed in terms of mg glutaraldehyde/mg PMP.
  • Figure 2 shows Kinetics of Mouse IgG Uptake by PMP, in terms of % mouse IgG uptake as a function of incubation time, in minutes.
  • Figure 3 shows Standard Curves for HCG generated on the ACS:180 ® instrument, in terms of RLU bound as a function of HCG concentration, which is expressed in terms of milli-International Units/ml.
  • Figure 4 shows Standard Curves for AFP generated on the ACS:180 ® instrument, in terms of RLU bound as a function of AFP concentration, which is expressed in terms of ng AFP/ml.
  • Figure 5 shows Standard Curves for PSA generated on the ACS:180 ® instrument, in terms of RLU bound as a function of PSA.concentration, which is expressed in units of ng PSA/ml.
  • Figure 6 shows Standard Curves for TSH generated on the ACS:180 ® instrument, in terms of RLU bound as a function of TSH concentration, which is expressed in units of micro-International Units of TSH/ml .
  • Figure 7 shows Standard Curves of LH generated on the ACS:180 ® instrument, in terms of RLU bound as a function of LH concentration, which is expressed in units of milli- International Units of LH/ml.
  • Magnetic particles have a number of uses in biological processes. Among these are the use of magnetic particles for the separation of biological components (i.e., a preparation function) . In addition, they are also used for analytical purposes. One of the analytical applications in which these particles are used is the immunochemistry area, where antibodies are attached to the magnetic particles. These antibodies are then reacted with an analyte of interest, and the application of a magnetic field will permit the separation of the analyte which has become attached to the magnetic particle.
  • a second antibody to a different epitope of the the analyte may have attached to it a label (e.g., acridinium ester) which can be detected by some analytical means (e.g., detection of luminescense) .
  • a label e.g., acridinium ester
  • some analytical means e.g., detection of luminescense
  • the immunochemical assays that are described herein can be conducted either manually or on an automated instrument, for example those instruments manufactured by Ciba Corning Diagnostics Corp. of Medfield, MA (e.g., the ACS:180 ® analyzer, which is an automated chemiluminescent immunochemical analyzer) .
  • Those assays run on the Ciba Corning instruments are generally based on the use of a chemiluminescent label, namely an acridinium ester-labeled antibody.
  • the magnetic particles which have been used in the biological process area have generally been those which have been coated with silane amine to enable the attachment of chemical entities to the surface.
  • Whitehead et al U.S. Patent No. 4,695,393 describes such a process for preparation of the silane amine-coated magnetic particle (also referred to as paramagnetic particles or PMP) .
  • PMP paramagnetic particles
  • variations of the Whitehead technology are well-known by those with skill in the art.
  • particles made out of glass or polymeric materials, and which have magnetic cores have also been utilized for the same purpose. See, for example, U.S. Patent No. 3,652,761 (Weetall) , 3,933,997 (Hersh et al) and literature from Bang Laboratories.
  • the first layer is "coated” on the particle itself, and a coating material used herein was silane amine.
  • the second layer is described as an “activation step”, and an activating material used herein was glutaraldehyde.
  • the third layer is "immobilized” on the particle, and one material immobilized herein was an antibody. This terminology is used herein.
  • a procedure for attaching the antibody or other molecule that will permit attachment to the target molecule is undertaken.
  • Various procedures are utilized for this purpose.
  • a procedure recommended by a manufacturer of magnetic particles includes the reaction of the magnetic particles with a 5% glutaraldehyde solution for 3 hours, removal of excess glutaraldehyde, reaction with the protein to be attached for 16 - 24 hours, followed by removal of excess protein. (See literature from Advanced Magnetics Inc.) This technique is typical of the coating procedures currently utilized. It has been unexpectedly found that the activating process can be significantly improved.
  • the concentration of glutaraldehyde used until the instant invention was in the range of approximately 1.25 mg to 2.0 mg of glutaraldehyde per milligram of magnetic particle.
  • the amount of reactive amine per unit of weight of the particle was never a factor until it was determined herein to have been overused in the past. Even at the low concentration of glutaraldehyde used herein (0.2mg/mg magnetic particle) , glutaraldehyde was still about 50 to 100 times excess over the amount of reactive amines on the magnetic particle.
  • the reduction in the activation time of glutaraldehyde was found to have a significant effect on the time required to complete the antibody immobilization process, thus allowing the process to be completed within a normal working day.
  • Coupling of glutaraldehyde to magnetic particles was found to be complete in approximately 1 hour.
  • Reasonably good performance was found when the glutaraldehyde coupling took place for between 30 and 90 minutes, with optimum performance being found at 1 hour.
  • uptake of the antibody molecule was found to be extremely fast (approximately 10 minutes) , while the subsequent bonding of the protein to the glutaraldehyde was found to be completed in approximately 6 hours.
  • An added advantage of the novel immobilization process is the improved sensitivity of the resulting particles used in some immunochemical assays, as shown in Table 1. .
  • the test tube was covered with two layers of parafilm and placed on a rotary shaker and mixed at 200 rpm for one hour at room temperature. At the end of one hour, PMP were magnetically separated and supernatant was removed. The PMP was washed five times with 0.5 ml 10 mM sodium acetate buffer, pH 5.5, each time. An antibody solution of purified monoclonal mouse anti-human chorionic gonadotrophin was prepared at 3.8 mg per ml concentration and 0.5 ml of the solution was added to the glutaraldehyde-activated PMP particles. PMP were mixed continuously for six hours at room temperature the same way as before. At the end of sixth hour, PMP were magnetically separated and supernatant was removed.
  • the PMP were then serially washed in 0.5 ml of each of the following wash solutions: 10 mM sodium acetate buffer, pH 5.5, 1 M NaCl, and 10 mM sodium phosphate buffer, pH 7.4.
  • PMP were resuspended in 2 ml of a "heat stress buffer" (usually 1.7% of BSA in 50 mM sodium phosphate buffer, pH 6.5) and transferred to a 15-ml polystyrene centrifugal tube with a screw-on cap.
  • the PMP was heat stressed at 50 C for 14-16 hours.
  • the PMP was magnetically separated and the supernatant was removed.
  • the PMP was washed twice with 2ml each time of the "TSH buffer " ( 0.1% BSA, 0.001% BGG in 10 mM Phosphate Buffered Saline pH 7.4 ) .
  • the final PMP were resuspended and stored in 1 ml of solid phase buffer, which contains BSA, BGG, normal mouse serum, normal sheep serum and antibiotics .
  • Both test lot and manufacturer (reference) lot solid phases were diluted to the same working concentration in the solid phase buffer.
  • Both solid phase reagents were run for binding performance on an ACS:180 ® analyzer. The result of standard curves of ACSTM HCG produced by the test and reference solid phases is shown in Fig.3. There is no significant difference between the two standard curves.
  • Solid phase was prepared by the same protocol as in ACSTM HCG except the antibody offered was monoclonal mouse anti- human alpha feto-protein, and the antibody loading was 2 mg per 10 mg of PMP .
  • the binding result between test and reference is shown in Figure 4.
  • Example 3 Preparation of Particles for ACSTM PSA (prostate specific antigen) assay Solid phase was prepared by the same protocol except the antibody offered was monoclonal mouse anti-human prostate-specific antigen and the antibody loading was 1.2 mg per 10 mg of PMP. The binding result of the test lot and the reference lot is shown in Figure 5.
  • Solid phase was prepared by the same protocol except the antibody offered was affinity purified sheep anti-human thyroid stimulating hormone and the antibody loading was 1.6 mg per 10 mg of PMP. The result is shown in Figure 6.
  • Solid phase was prepared by the same, protocol except the antibody offered was monoclonal mouse anti-human luteinizing hormone and the antibody loading was 2.0 mg per 10 mg of PMP. The result is shown in Figure 7.
  • solid phase antibody made by the new protocol is either equal to or better than the solid phase made by the corresponding reference protocol in terms of binding characteristics.
  • the new protocol is far better than the reference protocol in terms of simplicity and time saved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé amélioré permettant de préparer des particules magnétiques, recouvertes d'anticorps, qui sont utilisées pour effectuer la séparation de composants biologiques. Le nouveau procédé implique l'utilisation de glutaraldéhyde à des concentrations bien plus basses (approximativement 10 fois plus basses), et demande, ce qui est surprenant, beaucoup moins de temps, si l'on compare avec les procédés d'activation de particules. Ce nouveau procédé offre les avantages suivants: (1) il permet une élimination plus efficace du glutaraldéhyde en excédent dans le système de réaction, et, selon ce procédé, il n'est plus nécessaire de procéder à l'étape de trempe après l'utilisation des anticorps; (2) le procédé d'activation peut être réalisé bien plus rapidement que dans le passé, malgré une réduction importante de la concentration en glutaraldéhyde, ce qui permet de réaliser l'étape d'immobilisation des anticorps en un jour au lieu de deux; (3) les particules obtenues présentent une amélioration de 15 à 74 % de leur sensibilité, ce qui peut être observé dans certains dosages immunochimiques.
PCT/IB1995/000502 1994-06-23 1995-06-21 Procede de preparation de particules magnetiques utilisees pour realiser des analyses biologiques WO1996000394A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25736/95A AU2573695A (en) 1994-06-23 1995-06-21 Process for the preparation of magnetic particles used in biological analyses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26440194A 1994-06-23 1994-06-23
US08/264,401 1994-06-23

Publications (2)

Publication Number Publication Date
WO1996000394A1 true WO1996000394A1 (fr) 1996-01-04
WO1996000394B1 WO1996000394B1 (fr) 1996-01-25

Family

ID=23005913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/000502 WO1996000394A1 (fr) 1994-06-23 1995-06-21 Procede de preparation de particules magnetiques utilisees pour realiser des analyses biologiques

Country Status (2)

Country Link
AU (1) AU2573695A (fr)
WO (1) WO1996000394A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948538A (en) * 1996-11-21 1999-09-07 Saint-Gobain Village Glazing assembly comprising a substrate provided with a stack of thin layers for solar protection and/or thermal insulation
EP1013622A1 (fr) 1998-12-21 2000-06-28 Saint-Gobain Vitrage Substrat transparent comportant un revêtement antireflet
US9546108B2 (en) 2013-11-08 2017-01-17 Saint-Gobain Glass France Substrate coated with a stack of functional layers having improved mechanical properties

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125995A2 (fr) * 1983-05-12 1984-11-21 Advanced Magnetics, Inc. Particules magnétiques pour l'utilisation dans des séparations
GB2152664A (en) * 1984-01-04 1985-08-07 Serono Diagnostics Ltd Magnetic assay reagents
EP0180384A2 (fr) * 1984-11-01 1986-05-07 TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) Porteur-réactif sensible au magnétisme et procédé de préparation
EP0585868A2 (fr) * 1992-08-31 1994-03-09 Nippon Paint Co., Ltd. Particule magnétique et immunoessai l'utilisant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125995A2 (fr) * 1983-05-12 1984-11-21 Advanced Magnetics, Inc. Particules magnétiques pour l'utilisation dans des séparations
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
GB2152664A (en) * 1984-01-04 1985-08-07 Serono Diagnostics Ltd Magnetic assay reagents
EP0180384A2 (fr) * 1984-11-01 1986-05-07 TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) Porteur-réactif sensible au magnétisme et procédé de préparation
EP0585868A2 (fr) * 1992-08-31 1994-03-09 Nippon Paint Co., Ltd. Particule magnétique et immunoessai l'utilisant

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948538A (en) * 1996-11-21 1999-09-07 Saint-Gobain Village Glazing assembly comprising a substrate provided with a stack of thin layers for solar protection and/or thermal insulation
EP1013622A1 (fr) 1998-12-21 2000-06-28 Saint-Gobain Vitrage Substrat transparent comportant un revêtement antireflet
US9546108B2 (en) 2013-11-08 2017-01-17 Saint-Gobain Glass France Substrate coated with a stack of functional layers having improved mechanical properties

Also Published As

Publication number Publication date
AU2573695A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
US5302532A (en) Chromatographic supports having an immobilized flocculating agent and their use in immunoassays
EP0704058B1 (fr) Detection rapide d'analytes au moyen de recepteurs immobilises sur des particules solubles de l'ordre du sous-micron
CA1226215A (fr) Dosage immunologique des antigenes
US4672040A (en) Magnetic particles for use in separations
EP0105714B1 (fr) Immunoessai pour antigènes
EP0162914B1 (fr) Nouvelles analyses immunologiques et leurs kits d'utilisation
EP0125995B1 (fr) Particules magnétiques pour l'utilisation dans des séparations
US4397960A (en) Immunoassays using F(AB')2 fragments
US4143124A (en) Antigen-antibody analysis with solid phase rf and c1q
EP0124050B1 (fr) Une méthode pour l'exécution d'un immunoessai en phase solide employant un marquage luminescent
US5141848A (en) Confirmatory immunoassay using microparticle separation
EP0201079B1 (fr) Essai immunologique retardé en phase solide
WO1989006801A1 (fr) Procede de test et kit de reactif associe
US5691207A (en) Analyte assay using superaggregated complex as labelled reagent
JP2000206115A (ja) 抗体断片を用いた免疫凝集反応試薬
US6121056A (en) Random detection of antigens with antibodies immobilized on soluble submicron particles
GB2152664A (en) Magnetic assay reagents
WO1996000394A1 (fr) Procede de preparation de particules magnetiques utilisees pour realiser des analyses biologiques
US5196349A (en) Immunoassays for thyroid hormones using thyroglobulin
CA2169121C (fr) Immuno-essai par competition, utilisant des derives de produits a analyser transformes en complexes
EP0276719B1 (fr) Immuno-essai utilisant la neutralisation par microparticule
JP2002139496A (ja) タンパク質吸着担体の製造方法およびその担体を用いた測定方法
JPH06505803A (ja) マルチテスト免疫化学的試薬及びその使用方法
JPH08506902A (ja) イムノアッセイ及びｄｎａハイブリダイゼーションアッセイにおいて使用するための水溶性ポリマー
JP2001305137A (ja) 特異的複合体の固定化方法および測定方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642